BGM Group Ltd.
BGM · XNASCIK 1779578fmd_0QVHEZPH9Y9T9HFYWNN3NVN3C6Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Oct 01, 2017 to Sep 30, 2025, 12 periods
| Line item | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Total revenues | 50 | 46 | 50 | 57 | 65 | 46 | 25 | 38 |
| Cost of revenue | 42 | 36 | 42 | 51 | 59 | 45 | 21 | 32 |
| Net interest income | – | – | (0) | (0) | 0 | 0 | – | – |
| Gross profit | 8 | 10 | 8 | 6 | 6 | 2 | 4 | 6 |
| Research and development | – | 0 | 0 | 0 | 1 | 1 | 1 | 1 |
| Selling, general and administrative | 2 | 4 | 3 | 3 | 4 | 4 | 3 | 18 |
| Operating income | 6 | 6 | 5 | 2 | 2 | (3) | (1) | (13) |
| Interest expense | 0 | 0 | 0 | 0 | – | – | – | – |
| Other non-operating income (expense) | 0 | 1 | 1 | 1 | (1) | (5) | (2) | (7) |
| Income before taxes | 6 | 7 | 6 | 3 | 2 | (8) | (2) | (20) |
| Income tax expense | 1 | 1 | 1 | 0 | 0 | 0 | (1) | 0 |
| Net income from continuing operations | 5 | 5 | 5 | 3 | 1 | (8) | (2) | (20) |
| Net income | 5 | 6 | 5 | 3 | 1 | (8) | (1) | (20) |
| Net income to common shareholders | – | – | – | – | 1 | (8) | (1) | (20) |